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Abstract
Since angiotensin-(1-12) [Ang-(1-12)] is a non-renin dependent alternate precursor for the generation of cardiac Ang
peptides in rat tissue, we investigated the metabolism of Ang-(1-12) by plasma membranes (PM) isolated from human atrial
appendage tissue from nine patients undergoing cardiac surgery for primary control of atrial fibrillation (MAZE surgical
procedure). PM was incubated with highly purified
125I-Ang-(1-12) at 37uC for 1 h with or without renin-angiotensin system
(RAS) inhibitors [lisinopril for angiotensin converting enzyme (ACE), SCH39370 for neprilysin (NEP), MLN-4760 for ACE2 and
chymostatin for chymase; 50 mM each].
125I-Ang peptide fractions were identified by HPLC coupled to an inline c-detector.
In the absence of all RAS inhibitor,
125I-Ang-(1-12) was converted into Ang I (262%), Ang II (69621%), Ang-(1-7) (562%),
and Ang-(1-4) (261%). In the absence of all RAS inhibitor, only 22610% of
125I-Ang-(1-12) was unmetabolized, whereas, in
the presence of the all RAS inhibitors, 9867% of
125I-Ang-(1-12) remained intact. The relative contribution of selective
inhibition of ACE and chymase enzyme showed that
125I-Ang-(1-12) was primarily converted into Ang II (65618%) by
chymase while its hydrolysis into Ang II by ACE was significantly lower or undetectable. The activity of individual enzyme
was calculated based on the amount of Ang II formation. These results showed very high chymase-mediated Ang II
formation (2863.1 fmol6min
216mg
21, n=9) from
125I-Ang-(1-12) and very low or undetectable Ang II formation by ACE
(1.160.2 fmol6min
216mg
21). Paralleling these findings, these tissues showed significant content of chymase protein that
by immunocytochemistry were primarily localized in atrial cardiac myocytes. In conclusion, we demonstrate for the first time
in human cardiac tissue a dominant role of cardiac chymase in the formation of Ang II from Ang-(1-12).
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Introduction
It is well established that the renin-angiotensin system (RAS) is a
major regulatory hormonal network influencing cardiovascular
homeostasis, blood pressure, and fluid and electrolyte balance.
The bioactive angiotensin peptides generated from angiotensin I
(Ang I), angiotensin II (Ang II) and angiotensin-(1-7) [(Ang-(1-7)],
display independent and pleiotropic biological activities in vivo, and
interact with each other both in metabolic pathways and biological
effects [1]. Biochemical and physiological studies document the
existence of a tissue-based RAS within a variety of tissues including
the heart [2]. More recently, a renewed interest toward the
investigation of alternate mechanisms for Ang II formation
upstream from Ang I arose from the work of Nagata et al. [3],
who showed that Ang II could be formed by the dodecapeptide
angiotensin-(1-12) [Ang-(1-12)], an extended form of Ang I.
Prosser et al. [4,5] reported that Ang-(1-12) caused vasoconstrictor
effects that were abolished by inhibition of angiotensin converting
enzyme (ACE) or chymase. Additional evidence for a biological
action of Ang-(1-12) via Ang II formation were reported in studies
in which either the peptide was administered in the rat brain [6–8]
or following endogenous neutralization via injection of a selective
Ang-(1-12) antibody [9].
Expanding on the potential functional role of this dodecapep-
tide as an alternate substrate for the cellular generation of
angiotensin peptides, we showed that Ang-(1-12) was predomi-
nantly expressed in cardiac myocytes and proximal, distal, and
collecting renal tubules of both WKY and SHR [10]. Additional
studies demonstrated that Ang II formation from Ang-(1-12) did
not require the presence of renin [11,12] while others [4] showed a
potential role for ACE and chymase in the cleavage of Ang-(1-12)
into Ang II. A more definitive study of Ang-(1-12) in isolated
cardiac myocytes from WKY and SHR found that while both
ACE and chymase participated in Ang-(1-12) metabolism, a
greater influence of chymase was evident in cardiac myocytes
isolated from SHR [13]. This finding confirmed our previous
report of increased cardiac Ang-(1-12) concentrations in SHR
[10].
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demonstrated a functional role of endogenously expressed Ang-
(1-12) in the formation of angiotensin peptides [3–8,10,11,13–15],
no data exists as to whether this substrate is found in humans. This
study describes the existence of Ang-(1-12) in the human heart and
identifies the primary enzyme accounting for Ang-(1-12) metab-
olism in human atrial cardio myocytes.
Results
Localization of Ang-(1-12) in Human Atrial Tissue
Figure 1 documents the presence of immunoreactive (ir-) Ang-
(1-12) products in atrial tissue collected from human subjects using
a protein A purified polyclonal antibody directed to the COOH-
terminus of the full length of the human Ang-(1-12) sequence. The
ir-Ang-(1-12) staining is found primarily in the cytoplasm of atrial
cardiomyocytes, in agreement with findings in the rat’s heart [10].
Striking differences in staining of cardiomyocytes between Ang-(1-
12) peptide block and unblocked tissue slides were noted (Figure 1).
When viewed at higher magnification, almost all atrial cardiac
myocytes showed some degree of positive staining with the Ang-(1-
12) antibody (Figure 1).
125I-Ang-(1-12) Metabolism by Human Atrial Tissue
Under the conditions described in Methods, excellent separa-
tion of the radiolabeled products derived from the addition of
125I-
Ang-(1-12) with or without the RAS inhibitor cocktail were
obtained for Ang I, Ang II, Ang-(1-7), and the peaks correspond-
ing to Ang-(1-4) fragments.
125I-Ang-(1-12) hydrolysis was evident
in these human samples, with Ang II (69621%; n=9) being the
predominant form found within 60 minutes after addition of
125I-
Ang-(1-12) in the absence of all inhibitors (No RAS inhibitors)
(Table 1). Peak areas of the chromatogram corresponding to Ang I
(262%), Ang-(1-7) (562%), and Ang-(1-4) peptide fragments
(261%) were detected in the absence of all RAS inhibitors
(Table 1).
125I-Ang-(1-12) degradation was essentially prevented
when the substrate was added to plasma membranes exposed to
the cocktail of RAS inhibitors. In this condition (All RAS inhibitors),
9867% of the parent
125I-Ang-(1-12) remained unmetabolized
after 60 min incubation at 37uC (Table 1). A large amount of Ang
II formation (65618%) from the reaction mixture, whereas Ang-
(1-12) remained unmetabolized (9865%) following the removal of
lisinopril only (ACE inhibitor); in this latter condition, only a small
amount of Ang II formation (261%) was detected (Table 1).
The chromatograms depicting the effect of peptidase inhibition
on
125I-Ang-(1-12) metabolism are shown in Figure 2-panels A to
D. In the presence of all RAS inhibitors, the chromatogram shows
a large peak area of unmetabolized Ang-(1-12) along with very
small peaks of Ang I and Ang II (Figure 2-panel A), whereas in the
absence of all RAS inhibitors the peak area of unmetabolized Ang-
(1-12) is a small fraction of that observed in the presence of all
inhibitors. The major peak corresponds to Ang II while peaks
corresponding to the synthetic forms Ang I, Ang-(1-7), and Ang-(1-
4) are expressed minimally in the absence of all RAS inhibitors
(Figure 2-panel B). Ang peptides formation from
125I-Ang-(1-12) is
only 261% (Ang II) when only lisinopril is removed from the
cocktail of inhibitors (Figure 2-panel C), whereas the selective
removal of chymostatin from the cocktail of inhibitors has a
diametrically opposite effect. As shown in Figure 2-panel D, Ang II
formation from
125I-Ang-(1-12) metabolism represents now the
major peak accounting for 65618%. Removal of chymostatin is
also associated with the presence of a minor peak for Ang I
(462%). The proportion of Ang II produced from
125I-Ang-(1-12)
in the absence of chymostatin (Ang II formation 65618%;
P,0.05; n=9) was not significantly different than that observed
when
125I-Ang-(1-12) was incubated with human atrial mem-
branes in the absence of all inhibitors (Ang II formation 69621%;
n=9) (Table 1).
Relative Contributions of ACE or Chymase in Human
125I-
Ang-(1-12) Metabolism
Based on the Ang II product generated from
125I-Ang-(1-12)
under different combinations of RAS inhibitors, Figure 3 shows
the relative expression of Ang II-forming by ACE and chymase
activities in the plasma membranes isolated from human atrial
tissue for both male and female samples. All samples, regardless of
sex, expressed significantly high chymase contribution for Ang II
generation (2863.1 fmol Ang II formation6min
216mg
21)a s
compared to a much lower or non-detectable contribution of ACE
in forming Ang II (1.160.2 fmol Ang II formation6min
216mg
21)
from Ang-(1-12).
Figure 1. Localization of Ang-(1-12) in human atrial tissue.
Comparative adjacent sections of Ang-(1-12) immunoreactivity ob-
tained from human atrial tissue with protein A purified polyclonal
antibody produced by AnaSpec. A) Antibody (1:2,000 dilution) blocked
with 100 mmol/L of human Ang-(1-12) peptide, and B) Unblocked
antibody (1:2,000 dilution). (Magnification 400; scale bar is 50 mm).
doi:10.1371/journal.pone.0028501.g001
Ang-(1-12) Metabolism in Human Atrial Tissue
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chymostatin inhibitor reflected a selective inhibition of chymase,
we further evaluated the hydrolysis of the colorimetric substrate
(N-Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide; N-suc-AAPF-pNA) by
human plasma membrane in the absence and in the presence of
chymostatin. The pattern of N-suc-AAPF-pNA hydrolysis was
consistent with the chymase activity detected by the HPLC for
Ang II formation from
125I-Ang-(1-12). Again the hydrolysis of N-
suc-AAPF-pNA was completely blocked in the presence of
chymostatin in the reaction mixtures. For final verification of
our conclusions,
125I-Ang-(1-12) metabolism was evaluated in the
presence of the chymase specific inhibitor (TEI-F00806) [18]. In
this study, the hydrolysis of Ang-(1-12) by human plasma
membrane was prevented by 95% in the presence of TEI-
F00806 (100 mM).
Chymase Expression in Human Atrial Tissue
Chymase protein expression, determined in 8 of the 9 human
samples using a primary monoclonal anti-human chymase
antibody, showed an immunoreactive band (,30 KD) for chymase
protein (Figure 4). The ir-chymase bands were normalized with b-
actin and relative chymase protein expression in the human atrial
tissue was consistence with the HPLC results of chymase activity to
generate Ang II products from
125I-Ang-(1-12) (Figure 3). In
addition, a significant correlation was found between chymase
activity and protein expression (r=0.954, P,0.002).
Immunolocalization of chymase was also analyzed in these atrial
tissues by using an anti-mast cell chymase monoclonal antibody.
As illustrated in Figure 5, a strong immunostaing for the presence
of chymase was detected within the cardiac myocytes of atrial
tissue. Negative controls without primary antibody show no
staining for chymase (Figure 5).
Discussion
We show that human atrial tissue samples obtained from
patients undergoing cardiac interventions for correction of atrial
fibrillation expresses ir-Ang-(1-12) and converts
125I-Ang-(1-12)
into angiotensin peptides. The study also demonstrates that
chymase is the main metabolic pathway by which this extended
form of Ang I serves as a substrate for the generation of Ang II in
human atrial samples. Detection of ir-Ang-(1-12) in human atrial
tissue and the capability of this tissue to convert this extended form
of Ang I into Ang II are in keeping with other studies in which Ang
II was the predominant angiotensin peptide formed from
125I-
Ang-(1-12) in the isolated perfused heart of three normotensive
and two hypertensive rat strains [12] and in neonatal cardiac
myocytes from WKY and SHR [13]. The very low levels of Ang-
(1-7) found at the time when either all inhibitors were present or
only the chymase inhibitor was removed suggest a lower
abundance in these tissues of either ACE2 or other peptidases
known to contribute to the generation of Ang-(1-7) from Ang II
[1,17,18]. It is also possible that the presence of the aminopep-
tidase inhibitors, amastatin and bestatin, prevented further
conversion of Ang II into smaller fragments.
125I-Ang-(1-12) was cleaved efficiently in the absence of the
chymostatin inhibitor to values not different than those found
when Ang-(1-12) was incubated in the absence of any of the
inhibitors. In both conditions, labeled Ang II was the predominant
product detected 60 minutes after addition of
125I-Ang-(1-12). The
human Ang-(1-12) sequence is H-Asp
1-Arg
2-Val
3-Tyr
4-Ile
5-His
6-
Pro
7-Phe
8-His
9-Leu
10-Val
11-Ile
12-OH. Since the chymotryptic
cleavage sites for human chymase are the Tyr
4-Ile
5 and Phe
8-
His
9, these data suggest that chymase generates Ang II by direct
hydrolysis of the Phe
8-His
9 bond of Ang-(1-12). This interpretation
agrees with the finding that in our experiments Ang I formation
represented less than 2% of the Ang-(1-12) hydrolysis.
A critical role for chymase in accounting for the processing of
Ang-(1-12) is reinforced through the corresponding consistency of
the chymase activity measured in each of the human samples.
Since the atrial tissue employed in these studies was obtained from
subjects undergoing cardiac surgery for the treatment of heart
rhythm disorders (Table 2), we cannot exclude the possibility that
the relatively high chymase activity reflects increased expression of
this enzyme in this condition. Although an increase in cardiac
chymase activity has been reported in both clinical and
experimental forms of heart failure [19–23], several studies suggest
that in humans Ang II formation from Ang I is primarily
dependent upon chymase rather than ACE [19,20,22,24–27]. A
comparative study by Akasu et al. [28] in human, hamster, rat,
rabbit, dog, pig, and marmoset tissues demonstrated a primary
role of lung ACE in all species but human cardiac and lung tissues.
In these tissues, a chymase-like activity solely accounted for the
Ang II-forming activity. Balcells et al. [29] reported that chymase
rather than ACE was the predominant enzyme accounting for
intracardiac Ang II generation in humans, whereas Ang II forming
activity from ACE was higher in cardiac tissue obtained from
mouse, dog, rabbits, rat, and mice. The rodent heart might be an
exemption since Wei et al. [27] showed that mast-cell derived
chymase contributes to Ang II from Ang I. In their studies the
content of Ang II in left ventricular interstitial fluid was not altered
by high doses of an ACE inhibitor but was suppressed in the
presence of a chymase inhibitor [27]. It is possible that
upregulation of chymase expression or activity may occur in
conditions of ACE inhibition, since chronic ACE inhibition causes
a marked bradykinin/B2 receptor-mediated increase in cardiac
interstitial fluid chymase activity that does not occur in mast cell-
deficient KitW/KitW-v mice [27]. Becari et al. [30] reported an
80% inhibition of Ang I induced carotid artery vasoconstriction by
the administration of chymostatin in enalapril-treated SHR rats.
Since the atrial tissues were obtained from 7 of the 9 subjects not
Table 1. Comparative Effects of Selective Enzyme Inhibition
on
125I-Ang-(1-12) Metabolism by plasma membrane isolated
from human atrial appendage tissues.
Peptides
NO RAS
Inhibitors
All RAS
Inhibitors
Minus
Lisinopril
Minus
Chymostatin
Ang-(1-12)* 22610
a 98679 8 653 1 613
a
Ang I 2621 62N D4 62
Ang II 69621
a 2612 616 5 618
a
Ang-(1-7) 562N D N D N D
Ang-(1-4) 261N D N D N D
HPLC of human
125I-Ang-(1-12) metabolic products generated by plasma
membrane (50 mg) isolated from human atrial appendage incubated with or
without the presence of RAS inhibitors at 37uC for 60 min. Values are expressed
as % (Mean 6 SEM) of Ang peptides generated from
125I-Ang-(1-12). No RAS
inhibitors group: Only aminopeptidases inhibitors (amastatin & bestatin),
carboxypeptidases inhibitor (benzyl succinate) and PCMB; All RAS inhibitors
group: Above inhibitors+RAS inhibitors (lisinopril, SCH39370, MLN-4760 &
chymostatin); Minus RAS inhibitor group: One of the RAS inhibitor (lisinopril or
chymostatin) omitted at a time form the All RAS inhibitors group.. Results are the
average of nine human samples (n=9).
*Percent of
125I-Ang-(1-12) parent control remained unmetabolized after 60 min
incubated with plasma membrane (50 mg) at 37uC. ND=Not detected;
aSignificantly different (P,0.05) vs. corresponding group of All RAS inhibitors.
doi:10.1371/journal.pone.0028501.t001
Ang-(1-12) Metabolism in Human Atrial Tissue
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receptor blockers (Table 2), our findings imply a major and
independent role of cardiac chymase in the biotransformation of
125I-Ang-(1-12) to angiotensin peptides.
Our results and those discussed above indicate that species
differences may influence the contribution of ACE and chymase to
cardiac Ang II formation. Urata et al. [24–26,31] first showed in
human cardiac ventricles that formation of Ang II by a serine
proteinase-dependent enzyme accounted for 80% of Ang II
formation while less than 10% of the Ang II produced depended
upon ACE. Later studies showed that this serine proteinase was
structurally characterized as a human member of the chymase
group of enzyme which is not inhibited by ACE inhibitors [24–
26,31,32]. According to Fleming [33], chymase functions as a
tissue Ang II-forming enzyme in human heart, arteries, and lungs
while ACE accounts for the majority of Ang II formation from
Ang I in the circulation. Chymase broad functional activities
includes its participation in collagen IV turnover [34], hydrolysis
of apolipoprotein E [35], thrombin, and fibrin [36,37].
Although numerous studies confirmed that chymostatin is a
specific chymase inhibitor [4,5,13,16,20,28,29,32,38–45], this
inhibitor may also nonspecifically reduces the activity of cathepsin
G, cysteine proteases, and high-molecular weight proteasomes
[46]. A recent report suggested that elastase-2, primarily expressed
in human and mouse epidermis may represent an alternate
pathway for Ang II generation from Ang I in conditions of chronic
ACE inhibition in rats but not human vascular tissue [30]. While
our past studies did not exclude a potential contribution of a
Figure 2. Ang-(1-12) metabolism by human atrial tissue. The metabolism of
125I-Ang-(1-12) by plasma membrane isolated from human atrial
tissues was analyzed by HPLC coupled to an inline BioScan c-detector. The
125I-Ang-(1-12) was incubated with human plasma membrane for 60 min
at 37uC with or without the inhibitor cocktail and the metabolites were separated by HPLC. A: Chromatograms represent the hydrolysis of
125I-Ang-(1-
12) in the presence of all RAS inhibitors (All RAS inhibitor group containing lisinopril, SCH39370, MLN-4760, chymostatin, bestatin, amastatin, benzyl
succinate, and PCMB). B: Hydrolysis of
125I-Ang-(1-12) in the absence of all RAS inhibitors cocktail (No RAS inhibitors group containing only bestatin,
amastatin, benzyl succinate, and PCMB). C: Hydrolysis of
125I-Ang-(1-12) in the presence of the inhibitor cocktail that lacks only Lisinopril (No lisinopril
inhibitor group containing all inhibitors as described in ‘‘A’’ except ACE inhibitor). D: Hydrolysis of
125I-Ang-(1-12) in the presence of inhibitor cocktail
that lacks only chymostatin (No chymostatin group containing all inhibitors as described in ‘‘A’’ except chymase inhibitor). Before adding the
125I-Ang-
(1-12), the plasma membrane was pre-incubated with inhibitors (each added at a dose of 50 mM) for 15 min at 37uC. The arrow indicates the
retention time of
125I-Ang-(1-12) and its metabolic products. HPLC results are representative of three or more separate metabolism experiments for
each human sample.
doi:10.1371/journal.pone.0028501.g002
Ang-(1-12) Metabolism in Human Atrial Tissue
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rat [13], our current findings in human atrial myocytes suggest
that human elastase does not account for our findings. This
interpretation is based in part on the demonstration that
chymostatin inhibited the hydrolysis of the colorimetric N-suc-
AAPF-pNA substrate by human plasma membranes. Although N-
suc-AAPF-pNA is not hydrolyzed by human leukocyte elastase
[47], this finding did not exclude a contribution of human
pancreatic elastase. Moreover, our additional finding that the
orally active chymase inhibitor (TEI-F00806) [16] prevented the
hydrolysis of Ang-(1-12) by 95% strengthens the importance of
cardiac chymase as the primary enzyme accounting for Ang-(1-12)
metabolism in human samples. This interpretation is further
reinforced by the concurrent measurements of chymase protein, a
strong correlation between chymase activity and expression, and
the detection of chymase immunoreactive products in the atrial
human tissue.
While studies of Ang-(1-12) processing in cardiac myocytes from
neonatal rats showed a contribution of ACE and neprilysin to
Ang-(1-12) metabolism in WKY, an increase in cardiac chymase
activity in Ang-(1-12) metabolism was found in SHR [13]. Prosser
et al. [4,5] reported that both ACE and chymase contributed to
Ang-(1-12) metabolism in the vascular system and the heart of
Sprague Dawley rats. Since the Ang II generating capacity from
Ang-(1-12) by ACE appeared to be predominantly found in the
vasculature, these data suggest tissue specific differential roles for
ACE and chymase in Ang-(1-12) metabolism.
In summary, the demonstration of ir-Ang-(1-12) in human atrial
samples and the characterization of its degradation by chymase
now paves the way for a further exploration of the role of this
alternate substrate in the regulation of cardiac function and
disease. Identification of Ang-(1-12) in human samples is a
necessary prerequisite for further research since in the past an
extensive characterization of the synthetic tetradecapeptide Ang-
(1-14) as a source for Ang II formation met with failure because it
was found not to be expressed in human subjects [48,49]. On the
other hand, a recent study by Bujack-Gizycka [14] using mass
spectrometry coupled with liquid chromatography showed ex-vivo
formation of Ang-(1-12) from synthetic tetradecapeptide Ang-(1-
14) in the rat aorta. In their study, Ang-(1-14) was rapidly
converted to Ang-(1-12) and subsequent formation of Ang II, Ang-
(1-7), and Ang-(1-9) [14]. These data are in keeping with our
Figure 3. Chymase and ACE contribution to generate Ang II
from Ang-(1-12). Chymase and ACE enzyme mediated generation of
Ang II product from the metabolism of
125I-Ang-(1-12) (1 nmol/L) by
plasma membrane isolated from human atrial tissues. The contribution
of each enzyme (chymase, and ACE) activity (fmol Ang II formation6
min
216mg
21) were calculated based on Ang II product analysis by
HPLC in each human samples incubated with or without the
chymostatin and lisinopril (each added at a dose 50 mM) for 60 min
at 37uC. Data are expressed as mean 6 SEM; total n=9 (4 female).
doi:10.1371/journal.pone.0028501.g003
Figure 4. Chymase protein expression in human atrial tissue. Chymase protein expression in human atrial samples was analyzed by western
blotting using a primary monoclonal anti-human chymase antibody (CMA1 antibody from R&D System, Cat# MAB-4099; 2 mg/mL). The plasma
membrane (50 mg protein) were separated by gel electrophoresis and transferred on PVDF. Equal protein loading on each lane was confirmed by b-
actin detection (1:5,000 dilution). Level of protein expression was shown as relative O.D. ratio (chymase/b-actin) for each human sample.
doi:10.1371/journal.pone.0028501.g004
Ang-(1-12) Metabolism in Human Atrial Tissue
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Ang-(1-12) metabolism [11,12]. As discussed by Dell’Italia et al.
[21,22,50], non-ACE formation of Ang II is known to maintain
plasma and cardiac Ang II concentrations in heart failure subjects
treated with adequate doses of ACE inhibitors. The present studies
revealed a tissue pathway that may account for Ang II formation
in the heart through the direct conversion of Ang-(1-12) into Ang
II.
Materials and Methods
Ethics Statement
The study has been approved by the Wake Forest University
Medical Center (IRB# 00004355; approved on November 30th
2010). The human samples were collected from the patients
undergoing cardiac surgery (Table 2) at the Wake Forest
University Baptist Medical Center (Winston-Salem, NC, USA).
The Wake Forest Medical Center committee overseeing ethical
standards and regulatory compliance in human research at Wake
Forest School of Medicine specifically determined that consent was
not necessary for this study.
Reagents
Human angiotensin-(1-12) (.99% purity) was purchased from
GenScript USA Inc. (Piscataway, NJ). Lisinopril (ACE inhibitor)
and SCH39370 (neprilysin inhibitor) were obtained from Merck
Inc. (West Point, PA). MLN-4760 (ACE2 inhibitor) was obtained
from Millennium Pharmaceuticals (Cambridge, MA). Chymosta-
tin (chymase inhibitor), amastatin, bestatin, benzyl succinate and
p-chloromercuribenzoate (PCMB), N-suc-AAPF-pNA were pur-
chased from Sigma-Aldrich Co. (St. Louis, MO). The TEI-F00806
(a chymase specific inhibitor) was a gift from Teijin Pharma
(Tokyo, Japan).
125Iodine was purchased from PerkinElmer Life
and Analytical Sciences, Inc. (Waltham, MA). All other chemicals
used in this study were of analytical grade and were obtained from
Sigma (St. Louis, MO) and Fisher Scientific (Atlanta, GA).
Human Tissue (atrial appendage)
Human left atrial appendage tissue from 5 men (Mean 6 SD,
59613 yrs.) and 4 women (Mean 6 SD, 7563 yrs.) were obtained
from patients undergoing cardiac surgery at Wake Forest
University Baptist Medical Center (Winston-Salem, NC). All
patients underwent surgical excision of the left atrial appendage
(LAA) as a routine part of the MAZE surgical procedure [51].
Diagnosis, drug treatment and clinical status of all nine patients
are described in Table 2. The excised LAA tissue obtained from
these patients was kept in cold cardioplegic solution from the time
of removal, frozen within 15–30 minutes, and stored at 280uC
until metabolism studies. The use of these tissues was approved by
the Wake Forest University Medical Center Institutional Review
Board.
Histology and Immunohistochemistry
Left atrial tissues from human cardiac patient were fixed in 4%
paraformaldehyde for 24 h and then transferred into 70% ethanol.
After dehydration, the tissues were embedded in paraffin and each
section was cut in 5-mm thick sections. Immunohistochemistry was
performed using well characterized protein A purified polyclonal
antibody directed to the COOH-terminus of full length of human
Figure 5. Immunohistochemistry of human atrial tissue for
chymase. Immunostaining of human atrial tissue using an Anti-Mast
Cell chymase antibody (Abcam Inc., Cambridge, MA; Cat# ab2377)
revealed high expression of chymase within atrial cardiac myocytes (A).
Negative control without primary antibody shows no staining for
chymase (B). (Magnification 400; scale bar is 50 mm).
doi:10.1371/journal.pone.0028501.g005
Table 2. Diagnosis, drug treatment and clinical statement of
human heart patients.
Patient
Sex/age) Diagnosis
Surgical
Procedure
ACE
Inhibitors ARB
b-
Blocker
Male/55 yr MV defect MAZE+MV repair No No No
Male/54 yr AF MINI-MAZE No No Yes
Male/51 yr AF MINI-MAZE No No Yes
Male/54 yr ASD+AF MAZE+ASD repair No No No
Male/82 yr CAD MAZE+CBS No No Yes
Female/71 yr AF MINI-MAZE Yes No Yes
Female/76 yr AF MINI-MAZE No No Yes
Female/75 yr AF MAZE Yes No Yes
Female/77 yr AF MINI-MAZE No No Yes
Abbreviation: MV, mitral valve; AF, atrial fibrillation; CAD, Coronary artery
disease; ASD, Atrial septal defect; CBS, Cardiac bypass surgery; ACE, angiotensin
converting enzyme, and ARB, angiotensin receptor blocker.
doi:10.1371/journal.pone.0028501.t002
Ang-(1-12) Metabolism in Human Atrial Tissue
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1-Arg
2-Val
3-Tyr
4-Ile
5-His
6-Pro
7-Phe
8-
His
9-Leu
10-Val
11-Ile
12] (AnaSpec, San Jose, CA). The binding
affinity and cross-reactivity of protein A purified antibody (IgG)
was checked for human Ang-(1-12) and small Ang peptides [Ang I,
Ang II and Ang-(1-7)]. The binding affinity of this antibody for
human Ang-(1-12) was very high (EC50=34.762.0 fM) as
compared to Ang I (EC50=26.268.6 pM), Ang II
(EC50=0.2860.02 nM) and Ang-(1-7) (EC50 below detection).
The antibody was independently used to detect immunoreactive
Ang-(1-12) in human atrial tissue using the avidin-biotin
horseradish peroxidase techniques as previously reported by our
laboratory [10,11]. Briefly, slides were deparaffinized in xylene
(15 min), subsequently dipped in ethanol (100%, 95% and 75%,
respectively) and washed in double distilled water. The clear slides
were incubated in 3% hydrogen peroxide to block the endogenous
peroxidase. The sections were first blocked by 5% normal goat
serum in phosphate buffered saline (PBS) for 30 min at room
temperature and then incubated with protein A purified human
Ang-(1-12) primary antibody (1:2000 dilution in 1% BSA in PBS
with 2% normal goat serum) for overnight at 4uC. Sections,
independently treated with 5% normal goat serum in the absence
of the primary antibody, served as negative controls. Additional
control included sections treated with the primary antibody
preincubated with 100 mmol/L of the human Ang-(1-12) peptide
to which the antibodies were directed.
After incubating in primary antibody, each section was washed
three times in PBS and incubated with biotinylated goat anti-
rabbit secondary antibody (1:400 dilution in 1% BSA in PBS with
2% normal goat serum; Vector Laboratories Inc., Burlington, CA)
for 3 hrs. After washing the secondary antibody with PBS, sections
were stained with 3,39-diaminobenzidine (DAB, Sigma-Aldrich
Chemical Co. St. Louis, MO) in Tris-buffered saline (0.05 mol/L,
pH 7.6–7.7), and counterstained with hematoxylin before being
dehydrated and mounted. Photographs of the resultant immuno-
reactive staining were acquired using a bright-field Nikon
microscope system (Melville, NY), including a Diagnostic
Instruments Digital SPOT RT, three-pass capture, thermoelec-
trically cooled charged-coupled camera (Sterling Heights, MI),
and processed using the SPOT Advanced software.
Immunohistochemistry of chymase expression in human atrial
tissue slides was also performed as describe above. The atrial tissue
slides were incubated for 20 hrs at 4uC with Anti-mast cell
chymase mouse monoclonal primary antibody (1:100 dilution;
Abcam, Cambridge, MA; Catalog# ab2377). The PBS washed
slides were then treated with biotinylated goat anti-mouse
secondary antibody (1:200 dilution; Vector Laboratories Inc.,
Burlington, CA) for 60 min at room temperature. For negative
control, in place of primary antibody, slides were treated with only
normal goat serum.
Plasma membrane preparation
Membranes were prepared at 4uC in a manner similar to the
approaches previously described by our laboratory [52] and by
Urata et al. [26] Frozen atrial tissue (50–100 mg) was homoge-
nized at 4uC in 1 mL PBS (pH 7.4) in a Qiagen TissueLyzer
(Valencia, CA). The homogenate was centrifuged at low spin
(200 g) for 5 min at 4uC to remove the connective tissues and cell
debris. The supernatant was transferred into a new tube and
centrifuged at 28,000 g for 20 min at 4uC to collect the plasma
membrane. The pellet was resuspended in PBS and centrifuged as
described above. Finally, the pellet was resuspended in PBS and
stored at 280uC till its use for metabolism studies. The
concentration of each cardiac membrane preparation is expressed
in terms of protein concentration measured by Bradford Reagent
using bovine serum albumin (BSA) as the standard; the results
were normalized in terms of per mg protein.
125I-Ang-(1-12) Metabolism by Human Plasma
Membranes
Metabolism of human Ang-(1-12) by plasma membrane isolated
form atrial tissue was studied under different combinations of RAS
inhibitors as documented in Table 3.
For
125I-Ang-(1-12) metabolism studies, plasma membranes
(50 mg per reaction mixture) were preincubated for 15 min under
various combinations of RAS and peptidases inhibitors (50 mM
each). After preincubation of plasma membranes with the
inhibitors, human
125I-Ang-(1-12) (1 nmol/L; specific activity
3,900 cpm/fmol) was added to the reaction medium and
incubated for an additional 60 min at 37uC. At the end of the
incubation time, the reaction was stopped by adding equal volume
of 1% phosphoric acid, mixed well, and centrifuged at 28,000 g
for 20 min to remove the plasma membrane. The clear
supernatants were stored at 220uC until processing the samples
for Ang contents [Ang-(1-12), Ang I, Ang II and Ang-(1-7)] by
HPLC analysis. On the day of HPLC analysis, the samples were
filtered before separation by reverse-phase high-performance
liquid chromatography. We used a linear gradient from 10% to
50% mobile phase B at a flow rate of 0.35 mL/min at ambient
temperature. The solvent system consisted of 0.1% phosphoric
acid (mobile phase A) and 80% acetonitriles/0.1% phosphoric
acid (mobile phase B). The eluted
125I products were monitored by
an in-line flow-through gamma detector (BioScan Inc., Washing-
ton, DC). Products were identified by comparison of retention
time of synthetic [
125I] standard peptides and the data were
analyzed with Shimadzu LCSolution (Kyoto, Japan) acquisition
software. The iodination of human Ang-(1-12) and other
angiotensins were performed as described previously [53].
Contribution of Specific Enzyme (ACE or Chymase)
The contribution of specific enzyme (ACE or chymase) to
125I-
Ang-(1-12) hydrolysis were analyzed by measuring the amount of
Ang products generated after exposing
125I-Ang-(1-12) with
plasma membrane in the presence of all RAS inhibitors cocktail
and in the absence of specific enzyme inhibitors for ACE or
chymase only (as described above). Supernatants were collected
after exposing the
125I-Ang-(1-12) in the presence of the plasma
membrane for 60 min at 37uC under two different enzyme
inhibitors conditions (+All RAS inhibitors versus minus ACE/
chymase inhibitor only) and were analyzed by HPLC as described
above. The enzyme activity was calculated based on adding
1 nmol/L of
125I-Ang-(1-12) substrate to the reaction mixture and
determining the amount of Ang II product formation. Experi-
ments were performed three or more times and the enzyme
activity values were reported as fmoles of Ang II product
formation from
125I-Ang-(1-12) substrate per min per mg protein
(fmol Ang II formation6min
216mg
21).
Chymase activity was also monitored by evaluating the
hydrolysis of 1 mM N-suc-AAPF-pNA in the plasma membrane
of six human atrial tissues. Briefly, all assays were performed in a
total reaction volume of 200 mL in the 96-well microtiter plates
containing plasma membranes with or without the presence of
chymostatin (chymase inhibitor; 50 mM) as described above in
50 mM Tris buffer (pH 8.0) containing 1.5 M NaCl and 1%
dimethylsulphoxide. The increase in absorbance at 410 nm was
measured at 37uC for different time points (0–180 min) for the
released p-nitroaniline. In addition, Ang II formation from
125I-
Ang-(1-12) was also investigated in the absence and in the presence
of TEI-F00806 (100 mM; an orally active chymase-specific
Ang-(1-12) Metabolism in Human Atrial Tissue
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plasma membranes isolated from human atrial tissue (50 mg per
reaction mixture) and
125I-Ang-(1-12) were incubated in the
presence or absence of TEI-F00806 (as described above for
chymostatin) for 37uC for 60 min. At the end of incubation,
samples were analyzed by HPLC for Ang II formation from
125I-
Ang-(1-12).
Western blot Analysis of Human Chymase
The expression of chymase protein in human plasma mem-
brane samples were assessed by immunoblot technique as
previously described [54]. Briefly, the plasma membranes (50 mg
protein) were separated by gel electrophoresis (10% gel) and
transferred to polyvinylidene defluoridated membranes (PVDF).
The PVDF membranes were probed with a primary monoclonal
anti-human chymase antibody (CMA1 antibody from R&D
System, Minneapolis, MN, Cat# MAB4099; 2 mg/mL) and
mouse anti-b-actin (1:5,000; Sigma–Aldrich, St. Louis, MO,
Cat# A-5441). After incubation with the primary antibody, the
membranes were probed with the horseradish peroxidase-
conjugated secondary antibody (anti-mouse, 1:5,000; Pierce Inc.,
Rockford, IL, USA). Immune complexes were visualized using
ECL plus detection reagents (Pierce). Densitometric analysis was
performed by measuring the intensity of all Western Blotting
bands with the MCID imaging system (MCID Elite 7.0, Imaging
Research Inc., St. Catharines, ON, Canada).
Statistical Analysis
Experiments were repeated independently three or more times.
All values are reported as means 6 SEM. The Student’s t-test and
repeated-measures ANOVA followed by a Turkey’s post hoc test
for multiple comparisons were used to determine significant
differences at P,0.05 using GraphPad Prism 5.0 software (San
Diego, CA).
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